BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19111461)

  • 1. Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.
    Rheault TR; Caferro TR; Dickerson SH; Donaldson KH; Gaul MD; Goetz AS; Mullin RJ; McDonald OB; Petrov KG; Rusnak DW; Shewchuk LM; Spehar GM; Truesdale AT; Vanderwall DE; Wood ER; Uehling DE
    Bioorg Med Chem Lett; 2009 Feb; 19(3):817-20. PubMed ID: 19111461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
    Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
    Rusnak DW; Affleck K; Cockerill SG; Stubberfield C; Harris R; Page M; Smith KJ; Guntrip SB; Carter MC; Shaw RJ; Jowett A; Stables J; Topley P; Wood ER; Brignola PS; Kadwell SH; Reep BR; Mullin RJ; Alligood KJ; Keith BR; Crosby RM; Murray DM; Knight WB; Gilmer TM; Lackey K
    Cancer Res; 2001 Oct; 61(19):7196-203. PubMed ID: 11585755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors.
    Xu G; Abad MC; Connolly PJ; Neeper MP; Struble GT; Springer BA; Emanuel SL; Pandey N; Gruninger RH; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4615-9. PubMed ID: 18653333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.
    Jin Y; Li HY; Lin LP; Tan J; Ding J; Luo X; Long YQ
    Bioorg Med Chem; 2005 Oct; 13(19):5613-22. PubMed ID: 15993078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.
    Hayakawa M; Kaizawa H; Moritomo H; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Workman P; Waterfield MD; Parker P
    Bioorg Med Chem Lett; 2007 May; 17(9):2438-42. PubMed ID: 17339109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases.
    Suzuki N; Shiota T; Watanabe F; Haga N; Murashi T; Ohara T; Matsuo K; Omori N; Yari H; Dohi K; Inoue M; Iguchi M; Sentou J; Wada T
    Bioorg Med Chem Lett; 2012 Jan; 22(1):456-60. PubMed ID: 22101132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-((4-Aminopiperidin-1-yl)methyl)pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.
    Mastalerz H; Chang M; Chen P; Fink BE; Gavai A; Han WC; Johnson W; Langley D; Lee FY; Leavitt K; Marathe P; Norris D; Oppenheimer S; Sleczka B; Tarrant J; Tokarski JS; Vite GD; Vyas DM; Wong H; Wong TW; Zhang H; Zhang G
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4947-54. PubMed ID: 17606372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
    Lv PC; Zhou CF; Chen J; Liu PG; Wang KR; Mao WJ; Li HQ; Yang Y; Xiong J; Zhu HL
    Bioorg Med Chem; 2010 Jan; 18(1):314-9. PubMed ID: 19914835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors.
    Waterson AG; Stevens KL; Reno MJ; Zhang YM; Boros EE; Bouvier F; Rastagar A; Uehling DE; Dickerson SH; Reep B; McDonald OB; Wood ER; Rusnak DW; Alligood KJ; Rudolph SK
    Bioorg Med Chem Lett; 2006 May; 16(9):2419-22. PubMed ID: 16483772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
    Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.
    Ghosh S; Narla RK; Zheng Y; Liu XP; Jun X; Mao C; Sudbeck EA; Uckun FM
    Anticancer Drug Des; 1999 Oct; 14(5):403-10. PubMed ID: 10766295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
    Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
    Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors.
    Waterson AG; Petrov KG; Hornberger KR; Hubbard RD; Sammond DM; Smith SC; Dickson HD; Caferro TR; Hinkle KW; Stevens KL; Dickerson SH; Rusnak DW; Spehar GM; Wood ER; Griffin RJ; Uehling DE
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1332-6. PubMed ID: 19208477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
    J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines.
    Hubbard RD; Dickerson SH; Emerson HK; Griffin RJ; Reno MJ; Hornberger KR; Rusnak DW; Wood ER; Uehling DE; Waterson AG
    Bioorg Med Chem Lett; 2008 Nov; 18(21):5738-40. PubMed ID: 18842405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irreversible inhibitors of the epidermal growth factor receptor: thienopyrimidine core with α,β-unsaturated amide side chain.
    Yang XL; Wang TC; Lin S; Fan HX
    Arch Pharm (Weinheim); 2014 Aug; 347(8):552-8. PubMed ID: 24917121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.